Pharmacoeconomic review report: Fluocinolone acetonide intravitreal implant (Iluvien) (Knight Therapeutics Inc.)
Fluocinolone acetonide (FA) intravitreal implant (Iluvien), a corticosteroid, is indicated for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure. Iluvien i...
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
October 2019, 2019
|
| Edition: | Version: final |
| Series: | CADTH common drug review
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | Fluocinolone acetonide (FA) intravitreal implant (Iluvien), a corticosteroid, is indicated for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure. Iluvien is a non-biodegradable 0.19 mg intravitreal implant with a submitted price of $7,770 per implant. The recommended dosing schedule is one implant, which is designed to release FA over three years at a rate of approximately 0.2 mcg per day. FA implant was previously reviewed by CADTH in 2018. The manufacturer, however, chose to withdraw the submission during the review period. The manufacturer submitted a cost-utility analysis (CUA) that modelled patients with DME who had received at least one prior laser treatment as per the three-year FAME trials |
|---|---|
| Item Description: | "Indication: For the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure." |
| Physical Description: | 1 PDF file (34 pages) illustrations |